Evidence map›Paper›PMID 22653709›Full record

ArticleEuropean journal of immunology2012

Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity.

Tom Pembroke, Ian Rees, Kathleen Gallagher, Emma Jones, Paul Mizen, Timur Navruzov, Andrew Freedman, Ceri Fielding, Ian R Humphreys, Eddie C Y Wang and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Antigen-Specific CD4Frontiers in immunology · 2018
    Article
  3. Article
  4. Observational
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Tom PembrokeSchool of Medicine, Institute of Infection and Immunity, Cardiff University, The Henry Wellcome Building, Cardiff, UK.
Ian Rees
Kathleen Gallagher
Emma Jones
Paul Mizen
Timur Navruzov
Andrew Freedman
Ceri Fielding
Ian R Humphreys
Eddie C Y Wang
Awen M Gallimore
Andrew Godkin
Cardiff University · GB

Funding

Medical Research Council G0901119Wellcome Trust 082249
6 · The paper itself

Abstract

The ability to control HCV with IFN-α-based treatments provides an opportunity in humans to study how the rate of viral clearance in vivo impinges on the development of antiviral responses. Ex vivo (IFN-γ-producing) and cultured antiviral CD4(+) T cells, serum cytokines, and viral loads were measured repeatedly in a cohort of chronically HCV-infected subjects (n = 33) receiving IFN-α. Rapid control of virus indicated by an increased calculated rate of virus clearance, occurred in those subjects demonstrating absent/minimal T-cell responses (p < 0.0006). Surprisingly, in subjects who demonstrated the most robust T-cell responses (and reduced serum IL-10), there was actually a reduced rate of early virus clearance. A subsequent analysis of NK-cell function in available subjects (n = 8) revealed an inverse correlation between pretreatment NK-cell expression of NKp46 and the potential to upregulate cytotoxic function on exposure to IFN-α (p < 0.004), as well as the subsequent measured rate of viral clearance (p = 0.045). Thus, the CD4(+) T-cell response during IFN-α treatment appears to be shaped by the rate of innate virus suppression. These data suggest that individuals who respond most effectively to immune intervention may be most in need of subsequent vaccination to prevent reinfection.

Indexed as

AdultAgedAlanine TransaminaseCD4-Positive T-LymphocytesCell Growth ProcessesCohort StudiesFemaleHepacivirusHepatitis C, ChronicHumansInterferon-alphaInterleukin-10Killer Cells, NaturalMaleMiddle AgedNatural Cytotoxicity Triggering Receptor 1Alanine TransaminaseInterferon-alphaInterleukin-10Natural Cytotoxicity Triggering Receptor 1NCR1 protein, human

Identifiers

PMID22653709
PMCPMC3781703
OpenAlexW1559912331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.